The successes Isoray Medical celebrated, and the milestones attained in 2016, have set a strong foundation that will allow us to catapult forward into 2017. We expect to continue to build on these successes in 2017, as we leverage our new web presence to share the progress of Cesium-131.
Overall, we will continue to drive our mission of designing and developing innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.
Data being collected creates more support for the value of Cesium-131 in providing personalized options for cancer patients
We are excited about the number of facilities that are collecting data to support the different treatment applications of Cesium-131. We expect many of these centers to present their updated findings at various professional meetings over the course of 2017.
For example, key data on prostate cancer treatment with Cesium-131 is being collected by Dr. Brian J. Moran, MD with the Chicago Prostate Center. Dr. Moran is an experienced practitioner of prostate brachytherapy, and a championing physician employing Isoray’s Cesium-131 brachytherapy seeds. Dr. Moran has performed thousands of prostate seed implants and has proctored physicians from all over the United States and the world including Korea, Europe and Hong Kong.
Other centers collecting data include Dr. Jonathan Feddock, a championing physician, at the University of Kentucky who continues to explore the benefits of Cesium-131 for Gynecological cancers and the team at the Barrows Neurological Institute in Arizona which continues to collect data on the use of Cesium-131 in the treatment of brain tumors.
Isoray Medical, Cesium-131 and American Brachytherapy Society’s Annual Meeting
As always we are looking forward to participating in the American Brachytherapy Society’s annual meeting that will be held in April. With the “cancer moonshot” objective set forth by the Obama administration, there is an ever increasing focus on cancer treatments in the American healthcare system. This meeting will meet multiple industry needs: joining the clinical minds and industry professionals to encourage close collaboration, and broadening the world’s view by bringing attention to data highlighting brachytherapy as a better treatment option for many cancers.
Are you attending ABS? We would love to connect! Contact Michael Krachon our Vice President of Sales and Marketing to schedule a time.
The year of the patient
With the shift toward value-based care, healthcare is currently hyper focused on the relationship between cost, outcomes and the patient experience. Isoray’s Cesium-131 seeds provide better outcomes for the patient while decreasing the debilitating side effects that can accompany cancer treatment: lessening the time and ultimately the cost of treatment. So in 2017 we will be taking the time to tell our story while highlighting the talented Cesium pioneers that make positive patient experiences possible.
For example, Joe M. was diagnosed with prostate cancer in 2015 and was treated using Isoray’s Cesium-131 brachytherapy seeds. “Prior to receiving Cesium-131 treatment, I thought the side effects would be minimal and the cancer would be gone,” said Joe. “That is exactly what happened.”
This year has a lot in store for the Isoray team as we seek to create better products, better patient outcomes and broaden our network of physicians. To stay up-to-date with the latest Isoray announcements and Brachytherapy news, follow us on Linkedin and Twitter!
If you are a clinician or patient interested in learning more about the capabilities and benefits of Cesium-131 Brachytherapy contact Info@isoray.flywheelstaging.com.
